French drugmaker Sanofi Genzyme has completed process qualification runs at a plant in Framingham based on digital and continuous biologics production technologies. Sanofi announced today that following successful process qualification runs in the last quarter, it has inaugurated a digitally-enabled, continuous manufacturing facility at its site in Framingham, Massachusetts. Nicolas Kressmann, a spokesperson from Sanofi, told Bioprocess Insider that the plant represented an investment of €290 million ($320 million) between 2014 and 2018. The French Big Biopharma firm spends around…